Non-response to (statin) therapy: The importance of distinguishing non-responders from non-adherers in pharmacogenetic studies by Trompet, S. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Non-response to (statin) therapy: The importance of distinguishing non-
responders from non-adherers in pharmacogenetic studies
Author(s) Trompet, S.; Postmus, I.; Slagboom, P. E.; Heijmans, B. T.; Smit, R. A.
J.; Maier, A. B.; Buckley, Brendan M.; Sattar, N.; Stott, D. J.; Ford, I.;
Westendorp, R. G. J.; de Craen, A. J. M.; Jukema, J. W.
Publication date 2015-12-19
Original citation Trompet, S., Postmus, I., Slagboom, P. E., Heijmans, B. T., Smit, R. A.
J., Maier, A. B., Buckley, B. M., Sattar, N., Stott, D. J., Ford, I.,
Westendorp, R. G. J., de Craen, A. J. M. and Jukema, J. W. (2016),
'Non-response to (statin) therapy: the importance of distinguishing non-
responders from non-adherers in pharmacogenetic studies', European
Journal of Clinical Pharmacology, 72(4), pp. 431-437. DOI:
10.1007/s00228-015-1994-9
Type of publication Article (peer-reviewed)
Link to publisher's
version
https://link.springer.com/article/10.1007%2Fs00228-015-1994-9
http://dx.doi.org/10.1007/s00228-015-1994-9
Access to the full text of the published version may require a
subscription.
Rights ©The Author(s) 2015. This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and
indicate if changes were made.
http://creativecommons.org/licenses/by/4.0/
Item downloaded
from
http://hdl.handle.net/10468/8879
Downloaded on 2019-12-02T14:12:11Z
PHARMACOGENETICS
Non-response to (statin) therapy: the importance of distinguishing
non-responders from non-adherers in pharmacogenetic studies
S. Trompet1,2 & I. Postmus2 & P. E. Slagboom3 & B. T. Heijmans3 & R. A. J. Smit1,2 &
A. B. Maier4 & B. M. Buckley5 & N. Sattar6 & D. J. Stott7 & I. Ford8 &
R. G. J. Westendorp9 & A. J. M. de Craen2 & J. W. Jukema1,10,11
Received: 1 July 2015 /Accepted: 1 December 2015 /Published online: 19 December 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Purpose In pharmacogenetic research, genetic variation in
non-responders and high responders is compared with the
aim to identify the genetic loci responsible for this variation
in response. However, an important question is whether the
non-responders are truly biologically non-responsive or actu-
ally non-adherent? Therefore, the aim of this study was to
describe, within the PROspective Study of Pravastatin in the
Elderly at Risk (PROSPER), characteristics of both non-
responders and high responders of statin treatment in order
to possibly discriminate non-responders from non-adherers.
Methods Baseline characteristics of non-responders to statin
therapy (≤10 % LDL-C reduction) were compared with those
of high responders (>40 % LDL-C reduction) through a linear
regression analysis. In addition, pharmacogenetic candidate
gene analysis was performed to show the effect of excluding
non-responders from the analysis.
Results Non-responders to statin therapy were younger
(p = 0.001), more often smoked (p < 0.001), had a higher
alcohol consumption (p < 0.001), had lower LDL cholesterol
levels (p < 0.001), had a lower prevalence of hypertension
(p < 0.001), and had lower cognitive function (p = 0.035)
compared to subjects who highly responded to pravastatin
treatment. Moreover, excluding non-responders from pharma-
cogenetic studies yielded more robust results, as standard er-
rors decreased.
Conclusion Our results suggest that non-responders to statin
therapy are more likely to actually be non-adherers, since they
have more characteristics that are viewed as indicators of high
self-perceived health and low disease awareness, possibly
making the subjects less adherent to study medication. We
suggest that in pharmacogenetic research, extreme non-
responders should be excluded to overcome the problem that
non-adherence is investigated instead of non-responsiveness.
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Hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) are the most commonly pre-
scribed drugs for the prevention of cardiovascular disease
worldwide. Statins lower plasma cholesterol levels by 30–
50 % and are associated with a reduction of cardiovascular
events of 20–40 % [1]. Statins are generally well tolerated and
are believed to have relatively few side effects [2]. However,
clinical response is highly variable and not all subjects appear
to benefit from statin therapy, with roughly a third of treated
patients achieving the lipid lowering goals specified in inter-
national guidelines [1]. It is uncertain whether these subjects
are truly biologically unresponsive, or are actually non-
adherent to the statin therapy.
Pharmacogenetic studies aim to find genetic variation that
is responsible for the variable response to drug treatment. For
that purpose, high responders and non-responders are often
compared with the aim to identify genetic loci associated with
the variation in response [ 3, 4]. Particularly in whole genome
sequencing studies, only the two extreme phenotypes (i.e., the
extremely good responders and the non-responders) are cho-
sen to reduce costs and enhance efficiency [5]. However, for
correct interpretation of this comparison, it is essential to en-
sure that non-responders have actually taken the drug and are
not merely non-responders due to non-adherence.
The most suitable studies to investigate these pharma-
cogenetic effects are randomized controlled trials, since
adherence to medication is closely monitored, for example,
through questionnaires and pill count and increasingly
through electronic medication monitoring devices [6].
However, these monitoring systems do not provide abso-
lute certainty that subjects are actually adherent to their
medication [7]. Non-adherers can relatively easily bypass
the control mechanisms, e.g., by discarding drugs before
the pill count, which may easily lead to overestimation of
adherence [8]. Using data of the PROspective Study of
Pravastatin in the Elderly at Risk (PROSPER) [9, 10], we
describe baseline characteristics of differential responder
groups to statin treatment in order to find discriminatory
factors between biologically non-responders and likely
non-adherers. Furthermore, we propose how to deal with
the misclassification of Bfalse^ non-responders in pharma-
cogenetic analyses.
Methods
We used data from the PROSPER study [ 9, 10]. In short, the
PROSPER study is a prospective multicenter randomized
placebo-controlled trial to assess whether treatment with
40 mg daily pravastatin diminishes the risk of major vascular
events in elderly individuals. Men and women aged 70–
82 years were recruited if they had pre-existing vascular dis-
ease or were at increased risk of such disease due to smoking,
hypertension, or diabetes. A total number of 5804 subjects
were randomly assigned to pravastatin (n = 2891) or placebo
treatment (n = 2913). At baseline, a brief medical history was
taken, vital signs were recorded, and a fasting venous blood
sample was collected for biochemical and hematological
checks and for lipoprotein quantification. In addition, a
mini-mental state examination (MMSE) was conducted to test
for cognitive function, and subjects with an MMSE score of
24 or lower were excluded. The protocol of the PROSPER
study meets the criteria of the Declaration of Helsinki and was
approved by the medical ethics committees of each participat-
ing institution. Written informed consent was obtained from
all participating cohorts.
From the pravastatin users (n = 2891), we excluded all
subjects who were withdrawn from the PROSPER study dur-
ing follow-up due to refusal of study medication or did not
attend the follow-up visits (n = 346). For the remaining sub-
jects (n = 2545), response to statin treatment was defined as
the percentage of achieved LDL lowering. This was calculated
by dividing the difference between baseline and post-baseline
(mean of measurements at months 3, 6, 12, 24, and 36) LDL
levels by the baseline level and multiplying the result by 100.
If data of one or more of the measurements for one individual
was missing, we took the mean of the available measurements
of that individual as post-statin treatment measurement. These
data were available for 2519 subjects.
We then created five groups of achieved LDL lowering
(≤10, 10–20, 20–30, 30–40, >40 % LDL lowering) and com-
pared baseline characteristics between these groups. Based on
clinical experience, non-responders were defined as those sub-
jects achieving a 10 % or lower decrease in LDL cholesterol
levels and high responders were defined as those subjects
achieving a decrease of more than 40 %.
First, we assessed whether there were differences in
baseline characteristics between the five groups of
achieved LDL lowering using ANOVA. Baseline charac-
teristics included sex, age, education, smoking, alcohol
use, BMI, blood pressure, LDL cholesterol level, history
of hypertension, diabetes, vascular disease, and cognitive
function. We also assessed differences in baseline charac-
teristics between the high and non-responders with the
Student’s t test for continuous variables and the Pearson
chi-square test for categorical variables.
Second, we used binary logistic regression to assess the
relative risk of being a non-responder based on the clinical
characteristics that were significantly different between the
high and low groups in the first analysis. Continuousmeasure-
ments were dichotomized based on sex-specific medians. All
analyses were adjusted for age and country of origin, and
where necessary additionally adjusted for sex. Third, we cal-
culated the number of risk factors per subject and assessed the
association between the number of risk factors and non-
responder status with binary logistic regression analysis
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adjusted for age, sex, and country of origin.We were unable to
calculate the sum of risk scores in seven subjects, six of whom
were high responders, due to missing data.
Finally, we performed a pharmacogenetic candidate gene
study to show the effect of four well-established associated
SNPs with a variable response to statin therapy using four
analytic strategies [11]. The four SNPs (rs2900478
(SLCO1B1), rs445925 (APOE), rs464776 (SORT1/
CELSR2/PSRC1), and (rs10455872 (LPA) were extracted
from the Genome Wide Association Study (GWAS) per-
formed in the PROSPER study, named the PHASE study
(the PHArmacogenetic study of Statins in the Elderly) [12].
Genotyping was performed with the Illumina 660K beadchip,
and imputation of up to 2.5 million SNPs was based on the
HapMap 36 build. First, we performed a linear regression
analysis to investigate the effect of the four SNPs on the
achieved LDL lowering (%) in the total study sample
(n = 2272) adjusted for age, sex, country, and baseline LDL
levels. The total number of subjects is lower in this genetic
analysis since the GWAS has not been executed in all
PROSPER subjects, because of genotyping failure or because
subjects were excluded based on the GWAS quality control
criteria [12]. No subjects were excluded based on phenotypic
outliers. Second, we excluded the non-responders from the
sample and repeated the linear regression analysis
(n = 2167). Third, we compared the effect of the SNPs in a
case-control setting where the non-responders were set as the
cases and the high responders as controls by using binary
logistic regression adjusted for age, sex, country, and baseline
LDL levels (n = 669). Lastly, we performed the same analysis
using the low to moderate responders (10–20 % achieved
LDL lowering) as cases (n = 817).
Results
Table 1 shows the baseline characteristics of the five groups of
percentage LDL lowering with pravastatin treatment. There
were significant differences between the groups with re-
gard to sex, smoking status, history of hypertension, age,
Table 1 Association between
groups of % LDL lowering to
statin treatment and clinical
variables
% LDL lowering in response to pravastatin treatment
>40 %
(n = 734)
30–40 %
(n = 989)
20–30 %
(n = 502)
10–20 %
(n = 180)
≤10 %
(n = 114)
p
ANOVA
Categorical variables
(n, %)
Females 423 (58) 511 (52) 218 (43) 82 (46) 56 (49) <0.001
Current smokers 126 (17) 244 (25) 151 (30) 65 (36) 54 (47)* <0.001
History of
hypertension
503 (69) 620 (63) 301 (60) 98 (54) 58 (51)* <0.001
History of diabetes 79 (11) 104 (11) 58 (12) 16 (8) 7 (6) 0.485
History of vascular
disease
335 (46) 437 (44) 228 (45) 77 (43) 46 (40) 0.809
Country
Scotland 325 (44) 410 (42) 210 (42) 83 (46) 49 (43)
Ireland 248 (34) 364 (37) 200 (40) 71 (39) 51 (45)
The Netherlands 161 (22) 215 (22) 92 (18) 26 (14) 14 (12) 0.253
Continuous variables (mean, SE)
Age (years) 75.7 (0.12) 75.3 (0.11) 75.0 (0.15) 75.1 (0.24) 74.6 (0.29)* 0.001
BMI (kg/m2) 26.9 (0.15) 26.8 (0.13) 26.9 (0.18) 27.1 (0.33) 26.3 (0.42) 0.433
Education (years) 15.2 (0.08) 15.3 (0.07) 15.3 (0.10) 14.5 (0.11) 15.2 (0.19) <0.001
MMSE (points) 28.1 (0.06) 28.2 (0.05) 28.0 (0.07) 27.8 (0.12) 27.8 (0.14)* 0.010
Alcohol
(units/week)
3.5 (0.29) 5.0 (0.27) 7.2 (0.47) 7.2 (0.80) 6.5 (0.90)* <0.001
LDL cholesterol (mmol/
L)
4.0 (0.03) 3.8 (0.02) 3.7 (0.03) 3.4 (0.05) 3.4 (0.08)* <0.001
SBP (mmHg) 156.0
(0.80)
154.0
(0.70)
155.8
(0.99)
153.4
(1.59)
152.8 (2.14) 0.200
DBP (mmHg) 83.8 (0.41) 83.6 (0.36) 83.6 (0.50) 82.7 (0.83) 83.7 (1.04) 0.828
BMI body mass index,MMSE mini-mental state examination, LDL low-density lipoprotein, SBP systolic blood
pressure, DBP diastolic blood pressure
*Significant difference between the groups of ≤10 % and >40 % LDL lowering (all p < 0.05)
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education, cognitive function, alcohol use, and level of
LDL cholesterol. For most characteristics there was a lin-
ear trend with LDL lowering response, for alcohol use, we
observed a plateau effect for LDL lowering of 30 % and
lower. Moreover, when we compared the baseline charac-
teristics of the 114 non-responders with the characteristics
of the 734 high responders to pravastatin therapy, we found
that subjects who did not respond to pravastatin therapy
were on average 1 year younger (p = 0.001), more often
smoked and drank more alcohol (both p < 0.001), had lower
LDL cholesterol levels (p < 0.001), had lower prevalence of
hypertension (p < 0.001), and had lower cognitive function
(p = 0.035), compared to subjects who highly responded to
pravastatin therapy. Based on pill count, we defined a non-
adherer if they returned more than 18 (20 %) pills in the
preceding 90 days before their study visit (mean pill count
over maximum number of study visits per individual). Within
the subjects that highly responded to pravastatin therapy,
99.5 % were adherent to their study medication based on pill
count, whereas in the non-responders group this was reduced
to 78.6 %.
Next, we calculated the relative risk of being a non-
responder for the characteristics that significantly differed be-
tween high and non-responders with a binary logistic regres-
sion model (Table 2). The largest relative risk was found for
subjects who were current smokers (OR 3.96, 95 % CI 2.60–
6.03, p = 1.4 × 10−10). We also found a higher risk of being a
non-responder in subjects without a history of hypertension
(OR 2.01, 95 % CI 1.32–3.04, p = 0.001), with a lower cog-
nitive function (OR 1.46, 95 % CI 0.97–2.20, p = 0.068), with
higher alcohol intake (OR 1.73, 95 % CI 1.15–2.59,
p = 0.008), and with lower LDL cholesterol levels (OR 3.14,
95 % CI 2.05–4.80, p = 1.3 × 10−7). The association between
number of characteristics and response status is also shown in
Table 2. Compared to subjects with none or one risk factor, the
relative risk of being a non-responder gradually increased to
15.51 (95 % CI 5.83–41.27, p = 4.0 × 10−8) for subjects with
five characteristics. When the summary score was included in
the model as a continuous variable, the risk of being a non-
responder increased with 2.04 (95 % CI 1.69–2.46,
p = 1.1 × 10−13) per additional characteristic.
We examined the association of four well-established
SNPs involved in pharmacogenetics of statins using four
different research strategies (Table 3). By comparing the
results for analyses 1 and 2 where we investigated the
effect of the four SNPs with a continuous measurement
of achieved LDL lowering (%), it is shown that by exclu-
sion of the non-responders to statin therapy, the standard
errors (SE) decreases, indicating that indeed probably
noise is removed from these analyses. The beta stays more
or less consistent in the analyses; however, since the SE
decreases, also the p value decreases, and all four SNPs
show significant results. In the third analysis, we compared
the effect of the four SNPs in a case-control setting, where
the non-responders were set as the cases and the high re-
sponders as controls, by using binary logistic regression
adjusted for age, sex, country, and baseline LDL levels.
Surprisingly, none of the four SNPs showed a significant
association with statin response as was shown by the con-
tinuous analysis in the first two research strategies. How-
ever in analysis 4, we investigated the effect of the four
SNPs also in a case-control setting, by comparing the high
responders (controls) with the low-moderate responders
(cases), thereby again excluding the non-responders.
Table 2 Association between
baseline characteristics and being
a non-responder
High responders
(n = 734)
Non-responders
(n = 114)
OR
(95 % CI)a
p value
Smoking 126 (17) 54 (47) 3.96 (2.60–6.03) 1.43 × 10−10
No history of hypertension 231 (32) 56 (49) 2.01 (1.32–3.04) 0.001
Low MMSE 379 (52) 68 (60) 1.46 (0.97–2.20) 0.068
High alcohol 270 (37) 58 (51) 1.73 (1.15–2.59) 0.008
Low LDL cholesterol 298 (41) 78 (68) 3.14 (2.05–4.80) 1.31 × 10−7
Number of characteristics
≤1 297 (41) 20 (18) 1.0 (ref) –
2 256 (35) 26 (23) 1.71 (0.93–3.15) 0.086
3 126 (17) 36 (32) 4.77 (2.63–8.63) 2.56 × 10−7
4 38 (5) 20 (18) 7.26 (3.47–15.19) 1.43 × 10−7
5 10 (1) 11 (10) 15.51 (5.83–41.27) 3.97 × 10−8
Trend 2.04 (1.69–2.46) 1.13 × 10−13
OR odds ratio, LDL low-density lipoprotein, SBP systolic blood pressure,MMSEmini-mental state examination
a The OR represents the risk of being a non-responder when you are in the risk category. The continuous factors
were dichotomized based on sex-specific medians. Adjusted for age and country, the analyses for smoking and
hypertension were additionally adjusted for sex
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Now, two out of the four SNPs did again show a significant
association with LDL response (Table 3).
Discussion
In this study, we show that non-responders to statin treatment
differ from high responders with regard to baseline clinical
characteristics. Non-responders were more likely to smoke,
drank more alcohol, had a lower cognitive function, were less
likely to have hypertension, and had lower LDL cholesterol
levels. These characteristics can be considered as indicators of
higher self-perceived health and lower disease awareness, in-
dicating that non-responders are possibly less aware of the
benefits of using the study medication and are therefore more
likely to be non-adherent rather than biologically unrespon-
sive. Moreover, we show that exclusion of the non-responders
in pharmacogenetic analyses yields more robust results, as the
standard errors decreased after exclusion and p values
remained significant. These results indicate that pharmacoge-
netic studies that compare extreme phenotypes might be at
least partially biased by the phenomenon of some, perhaps
many, non-adherers probably being misclassified as non-
responders.
Few studies have investigated differences between non-
responders and high responders of statin therapy [13–16].
These showed that characteristics that are indicators of better
self-perceived health like age, the number of comorbidities,
and diet habits are different between high and non-responders
and are therefore more likely to be indicators of non-
adherence [17, 18]. However, we cannot rule out the possibil-
ity that these characteristics truly determine whether a subject
responds biologically differently to statin therapy. For exam-
ple, having higher LDL cholesterol baseline levels might be
associated with greater response to statin treatment simply
because a greater absolute, but also relative, change is possi-
ble, and also for example by making healthy lifestyle changes
on top of statin treatment. Therefore it is still not certain
whether this variable can help us to discriminate between
non-responders and non-adherers. This argument holds also
true for smoking and gender. For both characteristics, we can
think of plausible reasons that these are related to the amount
of adherence, but we cannot rule out the possibility of a true
pharmacological effect between these characteristics and stat-
in treatment. However, in various subgroup analyses within
the PROSPER study and in the existing literature, we found
no evidence of an interaction between any of the clinical char-
acteristics and statin response [10].
To draw more definite conclusions whether a non-
responder is a true non-adherer, the plasma level of the med-
ication should be determined. Unfortunately, we have not
measured this, but even if we had, this would unfortunately
Table 3 Comparison of four
genetic association analyses with
four well-known SNPs associated
with a pharmacogenetic effect of
statin therapy
Number Beta SE p value
rs2900478 (SLCO1B1)
1. All subjects 2272 0.021 0.0065 0.0014
2. Excluding non-responders 2167 0.020 0.0061 0.0008
3. High vs non-responders 669 −0.129 0.201 0.5209
4. High vs low-moderate responders 817 −0.682 0.158 0.0001
rs445925 (APOE)
1. All subjects 2272 −0.022 0.0088 0.0121
2. Excluding non-responders 2167 −0.021 0.0082 0.0097
3. High vs non-responders 669 0.398 0.327 0.2236
4. High vs low-moderate responders 817 0.170 0.262 0.5165
rs646776 (SORT1/CELSR2/PSRC1)
1. All subjects 2272 −0.014 0.0058 0.0129
2. Excluding non-responders 2167 −0.016 0.0054 0.0033
3. High vs non-responders 669 0.060 0.179 0.7388
4. High vs low-moderate responders 817 0.358 0.162 0.0268
rs10455872 (LPA)
1. All subjects 2272 0.0351 0.0123 0.0042
2. Excluding non-responders 2167 0.0288 0.0115 0.0122
3. High vs non-responders 669 −1.424 0.790 0.0714
4. High vs low-moderate responders 817 −0.682 0.873 0.4372
Analyses 1 and 2 were performed with linear regression with achieved LDL lowering (%) as outcome, adjusted
for age, sex, country, and baseline LDL levels. Analyses 3 and 4 were performed with binary logistic regression
adjusted for age, sex, country, and baseline LDL levels
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not solve our problem since a patient could easily restart med-
ication just prior to the plasma sample, while not taking the
medication on other days. The second best is pill count, al-
though also not considered highly reliable, especially not in
willingly non-compliant (possibility of discarding pills just
prior the pill count). Nevertheless we did keep track of the
number of pills used by the participants by a provisional pill
count. Based on pill count, we defined a non-adherer if they
returned more than 18 (20 %) pills in the preceding 90 days
before their study visit (mean pill count over maximum num-
ber of study visits per individual). Within the subjects that
highly responded to pravastatin therapy, 99.5%were adherent
to their study medication based on pill count, whereas in the
non-responders group, this was reduced to 78.6 %. However,
since multiple studies have shown that pill count is likely not a
valid instrument to measure true adherence [7, 8], we cannot
draw definite conclusions from these numbers.
In many pharmacogenetic studies, non-responders are
compared to high responders to investigate which genetic var-
iants are responsible for this difference in response [5]. Al-
though we believe that by using this design both statistical
power and efficiency are maximized, there is the possibility
of unintentionally investigating the non-adherent phenotype.
Hence, instead of finding genetic variation responsible for the
variation in response to therapy, genetic variation for adher-
ence is assessed. Therefore, we assessed the impact of four
different research strategies while performing pharmacogenet-
ic research. Our results suggest that by excluding non-re-
sponders, the noise of any possible non-adherence is reduced,
as the standard errors decreased, which cannot be the result of
a larger sample size. Moreover, through the use of a case-
control design for optimal efficiency, we demonstrated that
by using the non-responders as cases none of the four SNPs
were significantly associated whereas by using low-moderate
responders, two out of the four SNPs demonstrated a signifi-
cant association.
Therefore, based on these results, our suggestion is that in
pharmacogenetic research, instead of comparing the extreme
phenotypes (high versus non-responders), other research strat-
egies should be undertaken to find the genetic variation re-
sponsible for the difference in response to (statin) therapy. We
propose three different strategies that may be followed to di-
minish the likelihood of investigating non-adherence instead
of non-responsiveness. First, all subjects should be investigat-
ed using the full range of responsiveness as a continuous phe-
notype. This way, possible non-adherers among the extremely
non-responsive cases will exert limited influence on the re-
sults. The second proposed strategy is to exclude non-
responsive subjects to be sure that the non-adherers are ex-
cluded from the analysis. The third, the most sophisticated,
strategy is to use a propensity score, based on various clinical
characteristics associated with non-adherence, to match high
responders to non-responders when taking only the extremes
into a pharmacogenetic study for efficiency. This last analysis
will exclude any possible confounding from non-adherence
from the study. Unfortunately, we could not perform such
analysis in our data due to low statistical power.
In conclusion, pharmacogenetic studies that investigate the
difference between high and non-responders are almost cer-
tainly in part investigating the non-adherent phenotype, since
non-responders have clinical characteristics that coincide with
high self-perceived health and low-disease awareness which
are also very common in non-adherers. Other strategies, as
proposed herein, should be used to investigate the relation
between genetic variation and responsiveness to (statin)
treatment.
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